{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:40:46Z","timestamp":1777264846465,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01520-y","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:21:12Z","timestamp":1777252872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Genetic Characterization of Osteogenesis Imperfecta in Japanese Patients: Outcomes of Sequential Bisphosphonate Therapy"],"prefix":"10.1007","volume":"117","author":[{"given":"Chieko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-4405","authenticated-orcid":false,"given":"Takuo","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Kitabatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"1520_CR1","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, Bachinger HP et al (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 3:17052","journal-title":"Nat Rev Dis Primers"},{"key":"1520_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/MED.0000000000000367","volume":"24","author":"T Palomo","year":"2017","unstructured":"Palomo T, Vilaca T, Lazaretti-Castro M (2017) Osteogenesis Imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes 24:381\u2013388","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1520_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00223-024-01266-5","volume":"115","author":"M Jovanovic","year":"2024","unstructured":"Jovanovic M, Marini JC (2024) Update on the genetics of Osteogenesis Imperfecta. Calcif Tissue Int 115:891\u2013914","journal-title":"Calcif Tissue Int"},{"key":"1520_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in Osteogenesis Imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"1520_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/endrev\/bnab017","volume":"43","author":"M Jovanovic","year":"2022","unstructured":"Jovanovic M, Guterman-Ram G, Marini JC (2022) Osteogenesis Imperfecta: mechanisms and signaling pathways connecting classical and rare OI types. Endocr Rev 43:61\u201390","journal-title":"Endocr Rev"},{"key":"1520_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"key":"1520_CR7","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00198-015-3156-4","volume":"26","author":"R Kocijan","year":"2015","unstructured":"Kocijan R, Muschitz C, Haschka J, Hans D, Nia A, Geroldinger A, Ardelt M, Wakolbinger R, Resch H (2015) Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of Osteogenesis Imperfecta. Osteoporos Int 26:2431\u20132440","journal-title":"Osteoporos Int"},{"key":"1520_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00198-025-07423-2","volume":"36","author":"J Liu","year":"2025","unstructured":"Liu J, Zhang Y, Yu W, Sun L, Hu J, Jiang Y, Wang O, Xing X, Xia W, Li M (2025) TBS as a complementary tool for assessing vertebral fractures and spinal deformity in children and adolescents with Osteogenesis Imperfecta. Osteoporos Int 36:725\u2013735","journal-title":"Osteoporos Int"},{"key":"1520_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jocd.2018.09.001","volume":"22","author":"M Rehberg","year":"2019","unstructured":"Rehberg M, Winzenrieth R, Hoyer-Kuhn H, Duran I, Schoenau E, Semler O (2019) TBS as a tool to differentiate the impact of antiresorptives onCortical and trabecular bone in children with OsteogenesisImperfecta. J Clin Densitom 22:229\u2013235","journal-title":"J Clin Densitom"},{"key":"1520_CR10","doi-asserted-by":"publisher","first-page":"115584","DOI":"10.1016\/j.bcp.2023.115584","volume":"213","author":"J Munoz-Garcia","year":"2023","unstructured":"Munoz-Garcia J, Heymann D, Giurgea I, Legendre M, Amselem S, Castaneda B, Lezot F, William Vargas-Franco J (2023) Pharmacological options in the treatment of Osteogenesis Imperfecta: a comprehensive review of clinical and potential alternatives. Biochem Pharmacol 213:115584","journal-title":"Biochem Pharmacol"},{"key":"1520_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00223-024-01202-7","volume":"115","author":"P Arundel","year":"2024","unstructured":"Arundel P, Bishop N (2024) Medical management for fracture prevention in children with Osteogenesis Imperfecta. Calcif Tissue Int 115:812\u2013827","journal-title":"Calcif Tissue Int"},{"key":"1520_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00223-024-01263-8","volume":"115","author":"BM Misof","year":"2024","unstructured":"Misof BM, Fratzl-Zelman N (2024) Bone quality and mineralization and effects of treatment in Osteogenesis Imperfecta. Calcif Tissue Int 115:777\u2013804","journal-title":"Calcif Tissue Int"},{"key":"1520_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe Osteogenesis Imperfecta. N Engl J Med 339:947\u2013952","journal-title":"N Engl J Med"},{"key":"1520_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV Osteogenesis Imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977\u2013986","journal-title":"J Bone Miner Res"},{"key":"1520_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with Osteogenesis Imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150\u20132157","journal-title":"J Bone Miner Res"},{"key":"1520_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in Osteogenesis Imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30:929\u2013933","journal-title":"J Bone Miner Res"},{"key":"1520_CR17","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","volume":"23","author":"CG Shi","year":"2016","unstructured":"Shi CG, Zhang Y, Yuan W (2016) Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with Osteogenesis Imperfecta: a systematic review and meta-analysis. Am J Ther 23:e894-904","journal-title":"Am J Ther"},{"key":"1520_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","volume":"27","author":"GA Otaify","year":"2016","unstructured":"Otaify GA, Aglan MS, Ibrahim MM, Elnashar M, El Banna RA, Temtamy SA (2016) Zoledronic acid in children with Osteogenesis Imperfecta and Bruck syndrome: a 2-year prospective observational study. Osteoporos Int 27:81\u201392","journal-title":"Osteoporos Int"},{"key":"1520_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/jpem-2012-0016","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with Osteogenesis Imperfecta. J Pediatr Endocrinol Metab 25:485\u2013491","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1520_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis Imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"1520_CR21","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","volume":"27","author":"P Trejo","year":"2016","unstructured":"Trejo P, Rauch F (2016) Osteogenesis imperfecta in children and adolescents\u2014new developments in diagnosis and treatment. Osteoporos Int 27:3427\u20133437","journal-title":"Osteoporos Int"},{"key":"1520_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1359\/jbmr.1997.12.9.1463","volume":"12","author":"SL Hui","year":"1997","unstructured":"Hui SL, Gao S, Zhou XH, Johnston CC Jr., Lu Y, Gluer CC, Grampp S, Genant H (1997) Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 12:1463\u20131470","journal-title":"J Bone Miner Res"},{"key":"1520_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jbmr.1730","volume":"28","author":"HJ Kalkwarf","year":"2013","unstructured":"Kalkwarf HJ, Zemel BS, Yolton K, Heubi JE (2013) Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding. J Bone Miner Res 28:206\u2013212","journal-title":"J Bone Miner Res"},{"key":"1520_CR24","doi-asserted-by":"publisher","first-page":"e3887","DOI":"10.1210\/clinem\/dgac323","volume":"107","author":"HJ Kalkwarf","year":"2022","unstructured":"Kalkwarf HJ, Shepherd JA, Fan B, Sahay RD, Ittenbach RF, Kelly A, Yolton K, Zemel BS (2022) Reference ranges for bone mineral content and density by dual energy x-ray absorptiometry for young children. J Clin Endocrinol Metab 107:e3887\u2013e3900","journal-title":"J Clin Endocrinol Metab"},{"key":"1520_CR25","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1210\/jc.2011-1111","volume":"96","author":"BS Zemel","year":"2011","unstructured":"Zemel BS, Kalkwarf HJ, Gilsanz V et al (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160\u20133169","journal-title":"J Clin Endocrinol Metab"},{"key":"1520_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/jbmr.4520","volume":"37","author":"HJ Kalkwarf","year":"2022","unstructured":"Kalkwarf HJ, Shepherd JA, Hans D, Gonzalez Rodriguez E, Kindler JM, Lappe JM, Oberfield S, Winer KK, Zemel BS (2022) Trabecular bone score reference values for children and adolescents according to age, sex, and ancestry. J Bone Miner Res 37:776\u2013785","journal-title":"J Bone Miner Res"},{"key":"1520_CR27","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00198-019-05076-6","volume":"30","author":"Y Ohata","year":"2019","unstructured":"Ohata Y, Takeyari S, Nakano Y et al (2019) Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos Int 30:2333\u20132342","journal-title":"Osteoporos Int"},{"key":"1520_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1297\/cpe.2022-0027","volume":"31","author":"C Yamada","year":"2022","unstructured":"Yamada C, Kubota T, Ishimi T, Takeyari S, Kenichi Y, Nakayama H, Ohata Y, Fujiwara M, Kitaoka T, Ozono K (2022) A novel COL1A1 deletion\/insertion pathogenic variant in a patient with osteogenesis imperfecta. Clin Pediatr Endocrinol 31:205\u2013208","journal-title":"Clin Pediatr Endocrinol"},{"key":"1520_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/humu.20429","volume":"28","author":"JC Marini","year":"2007","unstructured":"Marini JC, Forlino A, Cabral WA et al (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28:209\u2013221","journal-title":"Hum Mutat"},{"key":"1520_CR30","doi-asserted-by":"publisher","first-page":"dmm049398","DOI":"10.1242\/dmm.049398","volume":"15","author":"N Garibaldi","year":"2022","unstructured":"Garibaldi N, Besio R, Dalgleish R, Villani S, Barnes AM, Marini JC, Forlino A (2022) Dissecting the phenotypic variability of osteogenesis imperfecta. Dis Model Mech 15:dmm049398","journal-title":"Dis Model Mech"},{"key":"1520_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.anorl.2019.05.004","volume":"136","author":"F Carre","year":"2019","unstructured":"Carre F, Achard S, Rouillon I, Parodi M, Loundon N (2019) Hearing impairment and osteogenesis imperfecta: literature review. Eur Ann Otorhinolaryngol Head Neck Dis 136:379\u2013383","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"1520_CR32","doi-asserted-by":"publisher","first-page":"110914","DOI":"10.1016\/j.ijporl.2021.110914","volume":"150","author":"JK Joseph","year":"2021","unstructured":"Joseph JK, Maharaj SH (2021) Osteogenesis Imperfecta and hearing loss in the paediatric population. Int J Pediatr Otorhinolaryngol 150:110914","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1520_CR33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/jbmr.220","volume":"26","author":"MS Cheung","year":"2011","unstructured":"Cheung MS, Arponen H, Roughley P, Azouz ME, Glorieux FH, Waltimo-Siren J, Rauch F (2011) Cranial base abnormalities in Osteogenesis Imperfecta: phenotypic and genotypic determinants. J Bone Miner Res 26:405\u2013413","journal-title":"J Bone Miner Res"},{"key":"1520_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s004310000505","volume":"159","author":"H Raoul","year":"2000","unstructured":"Raoul H, Cuno S, Vincent A, Hans E, Paul J (2000) Osteogenesis Imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr 159:615\u2013620","journal-title":"Eur J Pediatr"},{"key":"1520_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jbmr.2835","volume":"31","author":"N Bishop","year":"2016","unstructured":"Bishop N (2016) Bone material properties in Osteogenesis Imperfecta. J Bone Miner Res 31:699\u2013708","journal-title":"J Bone Miner Res"},{"key":"1520_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1210\/jc.2005-2036","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Travers R, Glorieux FH (2006) Pamidronate in children with Osteogenesis Imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91:511\u2013516","journal-title":"J Clin Endocrinol Metab"},{"key":"1520_CR37","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with Osteogenesis Imperfecta. J Clin Invest 110:1293\u20131299","journal-title":"J Clin Invest"},{"key":"1520_CR38","doi-asserted-by":"publisher","first-page":"ziae161","DOI":"10.1093\/jbmrpl\/ziae161","volume":"9","author":"D Farlay","year":"2025","unstructured":"Farlay D, Cornier M, Rizzo S et al (2025) Improvement of bone properties in children with osteogenesis imperfecta after pamidronate: a bone biopsy study. JBMR Plus 9:ziae161","journal-title":"JBMR Plus"},{"key":"1520_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s11914-017-0401-0","volume":"15","author":"A Biggin","year":"2017","unstructured":"Biggin A, Munns CF (2017) Long-term bisphosphonate therapy in Osteogenesis Imperfecta. Curr Osteoporos Rep 15:412\u2013418","journal-title":"Curr Osteoporos Rep"},{"key":"1520_CR40","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric Osteogenesis Imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779\u20131786","journal-title":"J Bone Miner Res"},{"key":"1520_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41436-018-0307-y","volume":"21","author":"LA Barber","year":"2019","unstructured":"Barber LA, Abbott C, Nakhate V, Do AND, Blissett AR, Marini JC (2019) Longitudinal growth curves for children with classical Osteogenesis Imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen. Genet Med 21:1233\u20131239","journal-title":"Genet Med"},{"key":"1520_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41436-018-0045-1","volume":"21","author":"M Jain","year":"2019","unstructured":"Jain M, Tam A, Shapiro JR et al (2019) Growth characteristics in individuals with Osteogenesis Imperfecta in North America: results from a multicenter study. Genet Med 21:275\u2013283","journal-title":"Genet Med"},{"key":"1520_CR43","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41390-023-02550-0","volume":"94","author":"ME Robinson","year":"2023","unstructured":"Robinson ME, Rauch D, Glorieux FH, Rauch F (2023) Standardized growth charts for children with osteogenesis imperfecta. Pediatr Res 94:1075\u20131082","journal-title":"Pediatr Res"},{"key":"1520_CR44","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1359\/jbmr.091109","volume":"25","author":"F Rauch","year":"2010","unstructured":"Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 25:1367\u20131374","journal-title":"J Bone Miner Res"},{"key":"1520_CR45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux FH, Langdahl B, Chapurlat R et al (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J Bone Miner Res 39:1215\u20131228","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01520-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01520-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:01:05Z","timestamp":1777262465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01520-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01520-y","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takuo Kubota has received research grants, honorarium, and consultant fees from Teijin Pharma. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of the University of Osaka (approval number: 688-11, 23386-2). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"61"}}